Hair loss, or alopecia, is a possible but uncommon side effect of zoledronic acid (Zometa, Reclast). Its occurrence can be difficult to isolate, as patients often receive other treatments, like chemotherapy or hormonal therapies, which more frequently cause hair loss.

A phase IV clinical study of FDA data: Hair loss is found as a side effect among people who take Zoledronic acid (zoledronic acid)

Learn about the side effects of zoledronic acid, from common to rare, for consumers and healthcare professionals.

A phase IV clinical study of FDA data: Hair loss is found as a side effect among people who take Zoledronic (zoledronic acid)

Zoledronic acid (Reclast) can trigger transient hair shedding, scalp dysesthesia, and a spectrum of skin reactions ranging from mild post-infusion flushing to rare but serious conditions including Stevens-Johnson syndrome.

While specific percentages vary across studies, hair loss is generally considered an uncommon side effect of zoledronic acid. Most studies indicate that it affects a relatively small percentage of patients, often less than 5%.

Common side effects of zoledronic acid may include: anemia. This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Do not use if you are pregnant.

Yes, hair loss is a potential side effect of Reclast. While it is not a common occurrence, some individuals may experience hair thinning or shedding while taking this medication.

Generally, hair loss associated with Reclast (zoledronic acid) is considered a temporary side effect, and hair is expected to grow back after discontinuing the medication and addressing any underlying nutrient deficiencies.

Telogen Effluvium is a temporary hair loss condition which causes the hair to shed diffusely from all over the head, giving the appearance of thinning. It can be triggered by a number of factors, most of which can be boiled down to some form of stress - either physical or mental.